Life Science Entrepreneurs Moving Into New Biotech Incubator Lab
With applicants for incubator lab space spiking to all-time highs in the past month, timing couldn't be better for the opening of the new MBC BioLabs facility San Carlos, Calif. Nineteen life science entrepreneurs are expected to snap up "rent a bench" space in the first few weeks, with the number increasing to 50 companies in a very short period of time.
Built specifically as life-science incubator space over the past 18 months, the new facility brings cutting-edge lab equipment, infrastructure and services to innovators and entrepreneurs so they can begin their discovery work week one, not year one. This is the third such lab operated by MBC BioLabs and its second in San Carlos. Its first lab opened in San Francisco in 2013. Our co-working incubator concept is proving to be critically important in speeding discovery and empowering entrepreneurial scientists to be fast, frugal and focused. Read full article.
2020 Amgen Golden Ticket Call for Proposals
Amgen is thrilled to be accepting submissions for the 2020 Amgen-MBC BioLabs Golden Ticket competition through June 24!
As a platinum sponsor of MBC BioLabs,Amgen will award two promising start-up companies with a year of free lab space (and more!) at MBC BioLabs.
Here's what you can expect with an Amgen - MBC BioLabs Golden Ticket in hand:
One-year FREE lab space at MBC BioLabs
Access to the shared amenities and services provided at MBC BioLabs
Mentorship by experienced Amgen scientists—we let you lead, ask for advice in any aspect of your science, and we'll provide insight and perspective
Access to talent and expertise across Amgen network
Nitrome Biosciences, a MBC BioLabs resident company developing a platform around a newly identified class of enzymes to target Parkinson's disease and other age-related disorders has closed a Series A financing of $38 million. Read full press release.
Caspr Biotech is developing a molecular diagnostics & detection platform powered by novel CRISPR Cas enzymes, currently focused on taking to market a COVID-19 assay.
CellFE (Cell Fluidics Engineering) brings innovative technology to engineer the next generation of cell therapies to fight cancer and other challenging diseases. CellFE has developed a unique microfluidic platform to solve one of the most pressing issues of therapeutic cell engineering – how to efficiently deliver gene-editing molecules into cells while preserving cell viability.